Tobi Podhaler
TOBI Podhaler is an inhaled formulation of Tobramycin, an aminoglycoside antibacterial, specifically designed for dry powder inhalation using the Podhaler device. It is used to treat or prevent chronic Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients.
Dosage by Body Weight
For patients 6 years of age and older, the standard dose is 112 mg (4 x 28 mg capsules) inhaled twice daily for a 28-day cycle, followed by 28 days off-therapy. Do not swallow the capsules. Administer doses as close to 12 hours apart as possible (no less than 6 hours apart).
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients under 6 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients under 6 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients under 6 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy have not been established in pediatric patients under 6 years of age.
- Body Weight
- 16-20 kg
- Dose
- 112 mg (4 capsules)
- Frequency
- Twice daily (every 12 hours)
- Tracking Notes
- Only if patient is 6 years of age or older. Dosing is fixed and not based on body weight.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric patients under 6 years of age. |
| 5-7 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric patients under 6 years of age. |
| 8-10 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric patients under 6 years of age. |
| 11-15 kg | Not recommended | N/A | Safety and efficacy have not been established in pediatric patients under 6 years of age. |
| 16-20 kg | 112 mg (4 capsules) | Twice daily (every 12 hours) | Only if patient is 6 years of age or older. Dosing is fixed and not based on body weight. |
Formulation
Purpose
Management of cystic fibrosis patients with Pseudomonas aeruginosa lung infections.
Generic Name
TobramycinScheduled Drug
No. This medicine is generally not treated as a scheduled/prescription-only drug in common consumer references, but local rules may vary.